The 4SC oncology strategy is primarily driven by epigenetics, a distinct and effective mechanism against many cancers. A potentially pivotal Phase II study with resminostat, an epigenetic cancer drug, in CTCL is due to start in H116, while partner Yakult should reveal Phase II Japanese trial data in HCC and NSCLC in 2016. Financings and/or collaborations may allow 4SC-202 and 4SC-205 to move into Phase II. We have made adjustments to our model to include a specific value for 4SC-202. Our rNPV
21 Mar 2016
Pioneering epigenetics in cancer
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pioneering epigenetics in cancer
4SC AG (VSC:FRA) | 0 0 4.2% | Mkt Cap: 249.2m
- Published:
21 Mar 2016 -
Author:
Linda Pomeroy -
Pages:
12
The 4SC oncology strategy is primarily driven by epigenetics, a distinct and effective mechanism against many cancers. A potentially pivotal Phase II study with resminostat, an epigenetic cancer drug, in CTCL is due to start in H116, while partner Yakult should reveal Phase II Japanese trial data in HCC and NSCLC in 2016. Financings and/or collaborations may allow 4SC-202 and 4SC-205 to move into Phase II. We have made adjustments to our model to include a specific value for 4SC-202. Our rNPV